Jim Tananbaum is the CEO and founder of Foresite Capital. The company specializes in the identification of healthcare leaders as is a dedicated, private equity fund. Prior to Foresite he founded GelTex Pharmaceuticals and Theravance. His investment experience comes from being one of the founders for Prospect Venture Partners and Sierra Ventures. He has taken the lead with numerous investments and is an expert at the creation of novel platforms.
Jim Tananbaum attended Yale as a computer science and electrical engineering major. His M.B.A. and M.D. were received from Harvard and his M.S. from the Institute of Technology in Massachusetts. His passion is in the combination of computer science and interdisciplinary hard sciences with healthcare. He believes the world is experiencing a period of growth driven by science and deep learning. You can visit LinkedIn to know more.
According to Business Wire, Jim Tananbaum is excited by the prospect of solving the unmet needs of healthcare. He believes in the future saliva, blood and tissue will be sequenced for treatments and disease prevention. He feels the biological insights available through data science and technology will yield results in drug development and genomic sequencing. He is looking forward to watching these areas develop and evolve.
Jim Tananbaum is a leader in his industry and has 25 years of experience in healthcare and investing. His focus is on financial, operational and strategic opportunities to build the healthcare business. He has played a significant role in Foresite Capital in investment organization, investment strategy and numerous portfolio companies. More details can be found on Crunchbase.
Before founding Foresite Capital, Mr. Tanenbaum founded two healthcare investment practices and two biopharmaceutical companies. After receiving his MS he founded GelTex Pharmaceuticals and brought two separate drugs to the market for under $80 million. In 1998 GelTex was acquired for approximately $1.6 billion and its leading drug has an annual revenue of over $200 million. The drug is called Renzela and still produces $1 billion annually even though 22 years have passed. Theravance and GSK together have a market capitalization of roughly $3.2 billion. Check out Insider Monkey for more info.